相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer
J. O'Shaughnessy et al.
ANNALS OF ONCOLOGY (2016)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
Jacqueline Lehmann-Che et al.
BREAST CANCER RESEARCH (2013)
The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?
T. E. Hickey et al.
MOLECULAR ENDOCRINOLOGY (2012)
A refined molecular taxonomy of breast cancer
M. Guedj et al.
ONCOGENE (2012)
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Min Ni et al.
CANCER CELL (2011)
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
Jessica L. L. Robinson et al.
EMBO JOURNAL (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
Laura C. Collins et al.
MODERN PATHOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
A. S. Doane et al.
ONCOGENE (2006)
Identification of molecular apocrine breast tumours by microarray analysis
P Farmer et al.
ONCOGENE (2005)
Drug therapy: Aromatase inhibitors in breast cancer
IE Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
